Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Biomed Res Int ; 2017: 3470893, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28761876

RESUMO

Iron deficiency anaemia (IDA) is the main extraintestinal manifestation affecting patients with inflammatory bowel disease (IBD). The Health Technology Assessment approach was applied to evaluate the sustainability of intravenous (IV) iron formulations in the Italian hospital setting, with particular focus on ferric carboxymaltose. Data on the epidemiology of IBD and associated IDA, in addition to the efficacy and safety of IV iron formulations currently used in Italy, were retrieved from scientific literature. A hospital-based cost-analysis of the outpatient delivery of IV iron treatments was performed. Organizational and ethical implications were discussed. IDA prevalence in IBD patients varies markedly from 9 to 73%. IV iron preparations were proven to have good efficacy and safety profiles, and ferric carboxymaltose provided a fast correction of haemoglobin and serum ferritin levels in iron-deficient patients. Despite a higher price, ferric carboxymaltose would confer a beneficial effect to the hospital, in terms of reduced cost related to individual patient management and additionally to the patient by reducing the number of infusions and admissions to healthcare facilities. Ethically, the evaluation is appropriate due to its efficacy and compliance. This assessment supports the introduction of ferric carboxymaltose in the Italian outpatient setting.


Assuntos
Anemia Ferropriva/tratamento farmacológico , Anemia Ferropriva/etiologia , Doenças Inflamatórias Intestinais/complicações , Ferro/administração & dosagem , Administração Intravenosa/métodos , Anemia Ferropriva/metabolismo , Compostos Férricos/metabolismo , Hemoglobinas/metabolismo , Hospitais , Humanos , Doenças Inflamatórias Intestinais/metabolismo , Infusões Intravenosas/métodos , Itália , Maltose/análogos & derivados , Maltose/metabolismo , Avaliação da Tecnologia Biomédica/métodos , Resultado do Tratamento
2.
Eur Rev Med Pharmacol Sci ; 17 Suppl 2: 99-104, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24443075

RESUMO

The high demand of Breath Tests (BT) in many gastroenterological conditions in time of limited resources for health care systems, generates increased interest in cost analysis from the point of view of the delivery of services to better understand how use the money to generate value. This study aims to measure the cost of C13 Urea and other most utilized breath tests in order to describe key aspects of costs and reimbursements looking at the economic sustainability for the hospital. A hospital based cost-analysis of the main breath tests commonly delivery in an ambulatory setting is performed. Mean salary for professional nurses and gastroenterologists, drugs/preparation used and disposable materials, purchase and depreciation of the instrument and the testing time was used to estimate the cost, while reimbursements are based on the 2013 Italian National Health System ambulatory pricelist. Variables that could influence the model are considered in the sensitivity analyses. The mean cost for C13--Urea, Lactulose and Lactose BT are, respectively, Euros 30,59; 45,20 and 30,29. National reimbursement often doesn't cover the cost of the analysis, especially considering the scenario with lower number of exam. On the contrary, in high performance scenario all the reimbursement could cover the cost, except for the C13 Urea BT that is high influenced by the drugs cost. However, consideration about the difference between Italian Regional Health System ambulatory pricelist are done. Our analysis shows that while national reimbursement rates cover the costs of H2 breath testing, they do not cover sufficiently C13 BT, particularly urea breath test. The real economic strength of these non invasive tests should be considered in the overall organization of inpatient and outpatient clinic, accounting for complete diagnostic pathway for each gastrointestinal disease.


Assuntos
Testes Respiratórios , Gastroenterologia/economia , Gastroenteropatias/diagnóstico , Gastroenteropatias/economia , Custos Hospitalares , Hospitais , Reembolso de Seguro de Saúde/economia , Programas Nacionais de Saúde/economia , Pessoal Técnico de Saúde/economia , Assistência Ambulatorial/economia , Biomarcadores/metabolismo , Dióxido de Carbono/metabolismo , Isótopos de Carbono/economia , Análise Custo-Benefício , Gases , Gastroenterologia/métodos , Gastroenteropatias/metabolismo , Humanos , Hidrogênio/metabolismo , Itália , Modelos Econômicos , Valor Preditivo dos Testes , Salários e Benefícios/economia , Ureia/economia
3.
G Ital Med Lav Ergon ; 34(3 Suppl): 266-8, 2012.
Artigo em Italiano | MEDLINE | ID: mdl-23405637

RESUMO

Several studies have shown that occupational exposure to anesthetic gases might be higher during pediatric surgery, probably due to the increased use of inhalational induction techniques. Our study aims to assess the level of exposure to sevoflurane in two rooms of pediatric surgery, using multi-point sampling method for environmental monitoring. The gas concentrations as well as its dispersion were measured in strategic points in the rooms for a total of 44 surgical interventions. Although the average of these concentrations has been rather low (1.32, SD +/- 1:55 ppm), the results obtained have documented a significant distribution kinetics difference inside the rooms as function of multiple factors among which there were the anesthetic technique used and the team involved. Therefore the method described allows to correctly analyze the spread of anesthetic gases and suggests a different risk stratification which may be dependent on the professional work.


Assuntos
Poluentes Ocupacionais do Ar/análise , Anestésicos Inalatórios/análise , Monitoramento Ambiental/métodos , Éteres Metílicos/análise , Exposição Ocupacional/análise , Salas Cirúrgicas , Humanos , Pediatria , Medição de Risco/métodos , Sevoflurano
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA